340B Drug Pricing Program

COVID-19 Resources

HRSA is working to keep 340B Program participants and stakeholders updated on the latest information regarding the coronavirus disease 2019 (COVID-19). All COVID-19 information related to the 340B Program will appear on the COVID-19 Resources page, and we will update resources as they become available.

 

The 340B Program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.

Manufacturers participating in Medicaid agree to provide outpatient drugs to covered entities at significantly reduced prices.

Eligible health care organizations/covered entities are defined in statute and include HRSA-supported health centers and look-alikes, Ryan White clinics and State AIDS Drug Assistance programs, Medicare/Medicaid Disproportionate Share Hospitals, children’s hospitals, and other safety net providers. See the full list of eligible organizations/covered entities.

To participate in the 340B Program, eligible organizations/covered entities must register and be enrolled with the 340B program and comply with all 340B Program requirements. Once enrolled, covered entities are assigned a 340B identification number that vendors verify before allowing an organization to purchase 340B discounted drugs.

Apexus LLC Awarded the 340B Prime Vendor Agreement

The Health Resources and Services Administration (HRSA) has awarded the 340B Prime Vendor Agreement to Apexus LLC after a competitive bid process.

The 340B Prime Vendor will continue to support the distribution of covered outpatient drugs through the 340B Drug Pricing Program and as a resource to 340B stakeholders.

Get more information and technical assistance via the 340B Prime Vendor Program HRSA Exit Disclaimer.

Date Last Reviewed:  March 2020